215 related articles for article (PubMed ID: 35021863)
1. A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma.
Minor DR; Kim KB; Tong RT; Wu MC; Kashani-Sabet M; Orloff M; Eschelman DJ; Gonsalves CF; Adamo RD; Anne PR; Luke JJ; Char D; Sato T
Cancer Biother Radiopharm; 2022 Feb; 37(1):11-16. PubMed ID: 35021863
[No Abstract] [Full Text] [Related]
2. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
Pelster MS; Gruschkus SK; Bassett R; Gombos DS; Shephard M; Posada L; Glover MS; Simien R; Diab A; Hwu P; Carter BW; Patel SP
J Clin Oncol; 2021 Feb; 39(6):599-607. PubMed ID: 33125309
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
[TBL] [Abstract][Full Text] [Related]
4. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
5. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.
Tong TML; van der Kooij MK; Speetjens FM; van Erkel AR; van der Meer RW; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Burgmans MC; Kapiteijn E
Trials; 2022 Feb; 23(1):137. PubMed ID: 35152908
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma.
Aedo-Lopez V; Gérard CL; Boughdad S; Gautron Moura B; Berthod G; Digklia A; Homicsko K; Schaefer N; Duran R; Cuendet MA; Michielin O
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267470
[TBL] [Abstract][Full Text] [Related]
7. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
9. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Tawbi HA; Forsyth PA; Algazi A; Hamid O; Hodi FS; Moschos SJ; Khushalani NI; Lewis K; Lao CD; Postow MA; Atkins MB; Ernstoff MS; Reardon DA; Puzanov I; Kudchadkar RR; Thomas RP; Tarhini A; Pavlick AC; Jiang J; Avila A; Demelo S; Margolin K
N Engl J Med; 2018 Aug; 379(8):722-730. PubMed ID: 30134131
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A
J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
13. Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis.
Yu IS; Wee K; Williamson L; Titmuss E; An J; Naderi-Azad S; Metcalf C; Yip S; Horst B; Jones SJM; Paton K; Nelson BH; Marra M; Laskin JJ; Savage KJ
Melanoma Res; 2022 Aug; 32(4):278-285. PubMed ID: 35726793
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases.
Arulananda S; Parakh S; Palmer J; Goodwin M; Andrews MC; Cebon J
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1183. PubMed ID: 32721131
[TBL] [Abstract][Full Text] [Related]
15. Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.
Tong TML; Burgmans MC; Speetjens FM; van Erkel AR; van der Meer RW; van Rijswijk CSP; Jonker-Bos MA; Roozen CFM; Sporrel-Blokland M; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Kapiteijn E
Cardiovasc Intervent Radiol; 2023 Mar; 46(3):350-359. PubMed ID: 36624292
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients.
Salaün H; de Koning L; Saint-Ghislain M; Servois V; Ramtohul T; Garcia A; Matet A; Cassoux N; Mariani P; Piperno-Neumann S; Rodrigues M
Oncoimmunology; 2022; 11(1):2116845. PubMed ID: 36092639
[TBL] [Abstract][Full Text] [Related]
17. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy.
Thompson JR; Lai-Kwon J; Morton RL; Guminski AD; Gonzalez M; Atkinson V; Sandhu S; Brown MP; Menzies AM; McArthur GA; Lo SN; Long GV; Bartula I
Immunotherapy; 2023 Jun; 15(8):593-610. PubMed ID: 37132182
[TBL] [Abstract][Full Text] [Related]
20. A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.
Chan PY; Hall P; Hay G; Cohen VML; Szlosarek PW
Pigment Cell Melanoma Res; 2017 Jan; 30(6):558-562. PubMed ID: 28640512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]